Pulmonx stock has seen its consensus fair value remain steady at $5.75 per share following a recent update to its narrative. Although the price target is unchanged, investors are watching closely, as shifting analyst perspectives point to renewed optimism supported by leadership changes and product potential. Stay tuned to discover how the Pulmonx narrative continues to evolve and how you can keep up with future valuation shifts.

Stay updated as the Fair Value for Pulmonx shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Pulmonx.

Analyst commentary has reflected both optimism and caution regarding Pulmonx, particularly following recent leadership changes and product developments. The following summarizes perspectives drawn from Lake Street’s latest research note.

???? Bullish Takeaways

Lake Street maintains a Buy rating on Pulmonx, though it has lowered its price target. The firm continues to view shares as attractive based on strong clinical validation of Zephyr valves and an expanding pipeline.

The return of former CEO Glen French and CFO Derrick Sung is seen as a positive signal by the firm. Lake Street expects Wall Street to welcome the leadership’s renewed involvement.

Analysts highlight the broad market opportunity and robust proof of concept supporting growth momentum.

Even with a revised $4 price target, Lake Street suggests the stock offers significant upside potential relative to current after-hours prices, citing an "approximate double."

???? Bearish Takeaways

Lake Street has lowered its price target dramatically, from $8 to $4, reflecting adjustments in valuation expectations and possible near-term risks.

The firm’s revision suggests tempered confidence about the speed or scale of Pulmonx’s path to higher valuation, despite ongoing product and leadership positives.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

Pulmonx issued revenue guidance for the third quarter of 2025, projecting approximately $21.5 million in total worldwide revenue.

Leadership changes were announced, with Steven S. Williamson resigning as Chief Executive Officer effective October 27, 2025. Glendon E. French was appointed President and CEO, and Derrick Sung, Ph.D., assumed the role of Chief Financial Officer on November 3, 2025, following the resignation of Mehul Joshi.

Pulmonx was removed from the S&P Global BMI Index, reflecting changes in index composition and company status.

A strategic partnership was formed between Pulmonx and Jaeger Medical to integrate advanced data qualification into the SentrySuite platform. This initiative is aimed at enhancing clinical decision-making for innovative respiratory therapies.

Consensus Fair Value remains unchanged at $5.75 per share.

The Discount Rate has decreased slightly from 9.45 percent to approximately 9.36 percent.

Revenue Growth projections are stable, holding at around 16.59 percent.

Net Profit Margin has increased from 12.64 percent to 13.54 percent.

The Future P/E ratio has declined moderately from 18.28x to 17.03x.

A Narrative is more than just numbers. It is your way to connect a company's story and strategy with future estimates of revenue, profit, and fair value. Narratives on Simply Wall St’s Community page let millions of investors see how stories shape forecasts, track fair value versus current price, and update automatically as news or results drop. This makes smarter investing easier than ever.

Follow the original Pulmonx Narrative to stay ahead of every market-moving update:

Access clear forecasts that link Pulmonx’s evolving leadership and clinical wins to future revenue, earnings, and target valuations.

Get timely risk and upside alerts as Narratives update with every new development or analyst revision.

See how other investors challenge or agree with the consensus, and learn exactly when current prices signal potential opportunity or risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include LUNG.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com